Pharmacological Insights: Mitochondrial ROS Generation by FNC (Azvudine) in Dalton's Lymphoma Cells Revealed by Super
Naveen Kumar1, Vikram Delu2, Ilya Ulasov3
1Department of Zoology, School of Basic and Applied Sciences, Raffles University, Neemrana, Rajasthan, 301705, India.
Abstract:
Nucleoside analogs are a common form of chemotherapy that disrupts DNA replication and repair, leading to cell cycle arrest and apoptosis. Reactive oxygen species (ROS) production is a significant mechanism through which these drugs exert their anticancer effects. This study investigated a new nucleoside analog called FNC or Azvudine, and its impact on ROS production and cell viability in Dalton's lymphoma (DL) cells. The study found that FNC treatment resulted in a time- and dose-dependent increase in ROS levels in DL cells. After 15 and 30 min of treatment with 2 and 1 mg/ml of FNC, mitochondrial ROS production was observed in DL cells. Furthermore, prolonged exposure to FNC caused structural alterations and DNA damage in DL cells. The results suggest that FNC's ability to impair DL cell viability may be due to its induction of ROS production and indicate a need for further investigation.
Insights
The novel chemotherapy drug Azvudine (FNC) increases reactive oxygen species (ROS) in Dalton's lymphoma cells, leading to cell damage and reduced viability. Further research is needed to explore its anticancer potential.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Nucleoside analogs are a cornerstone of chemotherapy, inducing cell cycle arrest and apoptosis.
- Reactive oxygen species (ROS) production is a key mechanism for anticancer drug efficacy.
- Dalton's lymphoma (DL) cells serve as a model for investigating novel chemotherapeutic agents.
Purpose of the Study:
- To investigate the impact of the new nucleoside analog, FNC (Azvudine), on ROS production and cell viability in DL cells.
- To elucidate the role of ROS in FNC-induced cytotoxicity.
- To assess the potential of FNC as an anticancer therapeutic.
Main Methods:
- Treatment of DL cells with varying concentrations and durations of FNC.
- Measurement of intracellular ROS levels, with a focus on mitochondrial ROS.
- Assessment of cellular structural integrity and DNA damage.
- Evaluation of cell viability following FNC exposure.
Main Results:
- FNC treatment induced a time- and dose-dependent increase in ROS levels in DL cells.
- Mitochondrial ROS production was significantly elevated after short-term FNC exposure (15-30 min).
- Prolonged FNC exposure resulted in observable structural alterations and DNA damage in DL cells, correlating with reduced cell viability.
Conclusions:
- FNC demonstrates potential as an anticancer agent by inducing ROS production and subsequent damage in DL cells.
- The observed increase in ROS, particularly mitochondrial ROS, appears to be a critical factor in FNC's cytotoxic effect.
- Further investigation into FNC's mechanism of action and therapeutic efficacy is warranted.
